06.24.14
Mequon, Wis.-based Titan Spine LLC, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, has expanded use of its Endoskeleton line of interbody devices to the United Kingdom and Spain.
“I am pleased to initiate use of Titan Spine’s Endoskeleton TAS interbody device and its specialized surface treatment,” said John Sutcliffe, M.D., founder of the London Spine Clinic, and first to use the Titan’s interbody fusion technology in the United Kingdom. “It is my belief that surface technology is the next significant innovation for spinal fusions due to the ability to affect a cellular response that promotes a more favorable osteogenic environment as compared to PEEK [polyetheretherketone] polymer implants.”
Titan’s Endoskeleton interbody fusion devices feature the company’s proprietary implant surface technology, consisting of a combination of roughened topographies at the macro, micro, and cellular levels. The combination of surface textures has been shown to promote an enhanced osteogenic environment when compared to smooth titanium or PEEK. As a result, Titan Spine’s Endoskeleton implants actively participate in the fusion process and function more than standard interbody spacers.
“The growing demand and use of Titan products demonstrates the expanding recognition that our engineered surface technology can be used to promote an enhanced environment for bone growth and ultimately fusion,” said Kevin Gemas, president for Titan Spine. “We look forward to continued adoption and building on this momentum to bring Endoskeleton devices to more physicians and patients throughout the European Union and beyond.”
“I am pleased to initiate use of Titan Spine’s Endoskeleton TAS interbody device and its specialized surface treatment,” said John Sutcliffe, M.D., founder of the London Spine Clinic, and first to use the Titan’s interbody fusion technology in the United Kingdom. “It is my belief that surface technology is the next significant innovation for spinal fusions due to the ability to affect a cellular response that promotes a more favorable osteogenic environment as compared to PEEK [polyetheretherketone] polymer implants.”
Titan’s Endoskeleton interbody fusion devices feature the company’s proprietary implant surface technology, consisting of a combination of roughened topographies at the macro, micro, and cellular levels. The combination of surface textures has been shown to promote an enhanced osteogenic environment when compared to smooth titanium or PEEK. As a result, Titan Spine’s Endoskeleton implants actively participate in the fusion process and function more than standard interbody spacers.
“The growing demand and use of Titan products demonstrates the expanding recognition that our engineered surface technology can be used to promote an enhanced environment for bone growth and ultimately fusion,” said Kevin Gemas, president for Titan Spine. “We look forward to continued adoption and building on this momentum to bring Endoskeleton devices to more physicians and patients throughout the European Union and beyond.”